7 min read
Monthly FDA Guidance and Regulatory News Review - April 2026
This April 2026 regulatory update highlights new policies on biomarker validation, expanded access to investigational...
June 14-18, 2026 – Philadelphia, PA
Veristat is excited to join industry leaders and innovators at the DIA 2026 Global Annual Meeting.
Join Steve Sibley, Vice President, Regulatory Strategy at Veristat, during three engaging sessions focused on practical approaches to submission readiness, operational efficiency, and cross-functional collaboration.
# 450 Medical Writing TED Experience
June 15, 2026 | 4:00 - 5:00 PM
Steve Sibley | Vice President, Regulatory Strategy | Veristat
Monica Chiaramonte | AstraZeneca
Anna Whitling | Alcon Laboratories
Explore emerging perspectives and innovative approaches in regulatory medical writing during this dynamic TED-style session featuring industry leaders and experts to help organizations navigate complex regulatory pathways and accelerate development programs.
# 608 Can You Complete Your Submission in 10 Weeks?
June 17, 2026 | 10:15 - 11:30 AM
Steve Sibley | Vice President, Regulatory Strategy | Veristat
Sharon Wolfe-Schwartz | Executive Director, Regulatory Medical Writing | Harmony Biosciences
Learn practical strategies for accelerating submission timelines while maintaining quality, compliance, and operational excellence.
# 620 Roundtable: Can You Complete Your Submission in 10 Weeks?
June 17, 2026 | 11:45 AM - 12:45 PM
Continue the conversation in an interactive roundtable discussion focused on real-world experiences, challenges, and solutions related to rapid submission readiness.
Whether you are preparing for an upcoming submission, optimizing regulatory operations, or exploring strategies to accelerate development timelines, our experts would welcome the opportunity to connect. Complete the form on this page to reserve time with our team during DIA 2026.
Veristat is a full-service CRO and consultancy helping sponsors advance complex and novel therapies through strategic regulatory guidance, clinical trial execution, and integrated development solutions.
For more than 30 years, Veristat has partnered with emerging and established biopharmaceutical companies to navigate development challenges with scientific expertise, operational excellence, and a collaborative approach. From early development through commercialization, our teams deliver tailored strategies designed to accelerate progress and support successful outcomes for life-changing therapies.
Meet with us at DIA 2026
Philadelphia, PA | June 14 - 18
7 min read
May 20, 2026 Veristat Blog
This April 2026 regulatory update highlights new policies on biomarker validation, expanded access to investigational...
3 min read
Apr 27, 2026 Veristat Blog
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...